Modulating the T Lymphocyte Immune Response via Secretome Produced miRNA: From Tolerance Induction to the Enhancement of the Anticancer Response
Open Access
- 13 May 2020
- book chapter
- Published by IntechOpen
Abstract
T cells are key mediators of graft tolerance/rejection, development of autoimmunity, and the anticancer response. Consequently, differentially modifying the T cell response is a major therapeutic target. Most immunomodulatory approaches have focused on cytotoxic agents, cytokine modulation, monoclonal antibodies, mitogen activation, adoptive cell therapies (including CAR-T cells). However, these approaches do not persistently reorient the systemic immune response thus necessitating continual therapy. Previous murine studies from our laboratory demonstrated that the adoptive transfer of polymer-grafted (PEGylated) allogeneic leukocytes resulted in the induction of a persistent and systemic tolerogenic state. Further analyses demonstrated that miRNA isolated from the secretome of polymer-modified or control allogeneic responses effectively induced either a tolerogenic (TA1 miRNA) or proinflammatory (IA1 miRNA) response both in vitro and in vivo that was both systemic and persistent. In a murine Type 1 diabetes autoimmune model, the tolerogenic TA1 therapeutic effectively attenuated the disease process via the systemic upregulation of regulatory T cells while simultaneously downregulating T effector cells. In contrast, the proinflammatory IA1 therapeutic enhanced the anticancer efficacy of naïve PBMC by increasing inflammatory T cells and decreasing regulatory T cells. The successful development of this secretome miRNA approach may prove useful treating both autoimmune diseases and cancer.Keywords
This publication has 71 references indexed in Scilit:
- Etanercept for the treatment of rheumatoid arthritisCochrane Database of Systematic Reviews, 2013
- The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44Nature Medicine, 2011
- Use of Nonobese Diabetic Mice to Understand Human Type 1 DiabetesEndocrinology and Metabolism Clinics of North America, 2010
- Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor–specified peripheral niche constraintsJournal of Experimental Medicine, 2010
- How Punctual Ablation of Regulatory T Cells Unleashes an Autoimmune Lesion within the Pancreatic IsletsImmunity, 2009
- MicroRNAs: Target Recognition and Regulatory FunctionsCell, 2009
- Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cellsCancer Gene Therapy, 2008
- The defect in T-cell regulation in NOD mice is an effect on the T-cell effectorsProceedings of the National Academy of Sciences, 2008
- The evolution of gene regulation by transcription factors and microRNAsNature Reviews Genetics, 2007
- Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA TargetsCell, 2005